{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nusinersen&page=2",
    "query": {
      "intervention": "Nusinersen",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nusinersen&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T04:26:27.273Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03878030",
      "title": "Effect of Nusinersen on Adults With Spinal Muscular Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adult Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2019-04-01",
      "completion_date": "2021-07-13",
      "has_results": false,
      "last_update_posted_date": "2023-03-20",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 1,
      "location_summary": "Great Neck, New York",
      "locations": [
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03878030"
    },
    {
      "nct_id": "NCT02052791",
      "title": "An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 47,
      "start_date": "2014-01-31",
      "completion_date": "2017-01-31",
      "has_results": false,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052791"
    },
    {
      "nct_id": "NCT02594124",
      "title": "A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 292,
      "start_date": "2015-11-04",
      "completion_date": "2023-08-21",
      "has_results": true,
      "last_update_posted_date": "2024-10-22",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 18,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02594124"
    },
    {
      "nct_id": "NCT01494701",
      "title": "An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "2 Years to 14 Years"
      },
      "enrollment_count": 28,
      "start_date": "2011-11-30",
      "completion_date": "2013-01-31",
      "has_results": false,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01494701"
    },
    {
      "nct_id": "NCT06532474",
      "title": "Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "5 Years to 20 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-10-29",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06532474"
    },
    {
      "nct_id": "NCT01780246",
      "title": "An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "2 Years to 15 Years"
      },
      "enrollment_count": 18,
      "start_date": "2013-01-31",
      "completion_date": "2014-02-28",
      "has_results": false,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01780246"
    },
    {
      "nct_id": "NCT04488133",
      "title": "A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Muscular Atrophy, Spinal"
      ],
      "interventions": [
        {
          "name": "Nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "36 Months",
        "sex": "ALL",
        "summary": "2 Months to 36 Months"
      },
      "enrollment_count": 46,
      "start_date": "2021-01-04",
      "completion_date": "2025-10-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 9,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04488133"
    },
    {
      "nct_id": "NCT04591678",
      "title": "Adults With SMA Treated With Nusinersen",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "nusinersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 15,
      "start_date": "2018-10-01",
      "completion_date": "2021-06-25",
      "has_results": false,
      "last_update_posted_date": "2021-09-22",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04591678"
    },
    {
      "nct_id": "NCT05386680",
      "title": "Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "OAV101",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 27,
      "start_date": "2023-01-12",
      "completion_date": "2024-11-29",
      "has_results": true,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Norfolk, Virginia • Madison, Wisconsin",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05386680"
    },
    {
      "nct_id": "NCT02292537",
      "title": "A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spinal Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "Nusinersen",
          "type": "DRUG"
        },
        {
          "name": "Sham procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 126,
      "start_date": "2014-11-24",
      "completion_date": "2017-02-20",
      "has_results": true,
      "last_update_posted_date": "2021-02-17",
      "last_synced_at": "2026-09-18T04:26:27.273Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02292537"
    }
  ]
}